ERBB2 and breast carcinoma: Unlike hormone receptor-positive or HER2-positive breast cancers, TNBC lacks targeted therapies, leaving chemotherapy as the mainstay of treatment and underscoring the urgent need for novel biomarkers and therapeutic strategies [5,6].